{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T21:00:54Z","timestamp":1788469254277,"version":"build-2803163510"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T00:00:00Z","timestamp":1548374400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr HIV\/AIDS Rep"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s11904-019-00436-7","type":"journal-article","created":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T11:17:07Z","timestamp":1548415027000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Medications for Treatment of Opioid Use Disorder among Persons Living with HIV"],"prefix":"10.1007","volume":"16","author":[{"given":"Laura","family":"Fanucchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra A.","family":"Springer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Todd","family":"Korthuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,25]]},"reference":[{"key":"436_CR1","volume-title":"Results from the 2016 National Survey on Drug Use and Health: Detailed Tables","author":"Center for Behavioral Health Statistics and Quality","year":"2017","unstructured":"Center for Behavioral Health Statistics and Quality. Results from the 2016 National Survey on Drug Use and Health: Detailed Tables. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2017."},{"issue":"50","key":"436_CR2","first-page":"1378","volume":"64","author":"Centers for Disease Control and Prevention","year":"2016","unstructured":"Centers for Disease Control and Prevention. Increases in Drug and Opioid Overdose Deaths - United States, 2000-2014. Morb Mortal Wkly Rep. 2016;64(50):1378\u201382.","journal-title":"Morb Mortal Wkly Rep"},{"key":"436_CR3","unstructured":"Centers for Disease Control and Prevention. Provisional Drug Overdose Death Counts, in Vital Statistics Rapid Release, N.C.f.H. Statistics, Editor. 2018."},{"issue":"5","key":"436_CR4","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1056\/NEJMp1507252","volume":"373","author":"SA Strathdee","year":"2015","unstructured":"Strathdee SA, Beyrer C. Threading the needle--how to stop the HIV outbreak in rural Indiana. N Engl J Med. 2015;373(5):397\u20139.","journal-title":"N Engl J Med"},{"key":"436_CR5","unstructured":"Schumaker E. Opioids have sparked an HIV outbreak in Massachusetts, in Huffington Post. 2018."},{"issue":"3","key":"436_CR6","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/QAI.0000000000001098","volume":"73","author":"MM Handel Van","year":"2016","unstructured":"\u2022\u2022 Van Handel MM, et al. County-level vulnerability assessment for rapid dissemination of HIV or HCV infections among persons who inject drugs, United States. J Acquir Immune Defic Syndr. 2016;73(3):323\u201331. This study is an evaluation of the US counties at highest risk of an HIV outbreak associated with injection drug use.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"16","key":"436_CR7","first-page":"443","volume":"64","author":"C Conrad","year":"2015","unstructured":"Conrad C, Bradley HM, Broz D, Buddha S, Chapman EL, Galang RR, et al. Community outbreak of HIV infection linked to injection drug use of oxymorphone--Indiana, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(16):443\u20134.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"436_CR8","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12879-015-0913-0","volume":"15","author":"P Azar","year":"2015","unstructured":"Azar P, Wood E, Nguyen P, Luma M, Montaner J, Kerr T, et al. Drug use patterns associated with risk of non-adherence to antiretroviral therapy among HIV-positive illicit drug users in a Canadian setting: a longitudinal analysis. BMC Infect Dis. 2015;15:193.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"436_CR9","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1007\/s10461-017-1808-4","volume":"22","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Wilson TE, Adedimeji A, Merenstein D, Milam J, Cohen J, et al. The impact of substance use on adherence to antiretroviral therapy among HIV-infected women in the United States. AIDS Behav. 2018;22(3):896\u2013908.","journal-title":"AIDS Behav"},{"issue":"8","key":"436_CR10","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1093\/cid\/ciw416","volume":"63","author":"AJ Low","year":"2016","unstructured":"\u2022 Low AJ, et al. Impact of opioid substitution therapy on antiretroviral therapy outcomes: a systematic review and meta-analysis. Clin Infect Dis. 2016;63(8):1094\u2013104. This study is a review and meta-analysis of the impact of treatment with methadone and buprenorphine on HIV treatment outcomes.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"436_CR11","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1007\/s11524-010-9438-4","volume":"87","author":"SA Springer","year":"2010","unstructured":"Springer SA, Chen S, Altice FL. Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment. J Urban Health. 2010;87(4):592\u2013602.","journal-title":"J Urban Health"},{"issue":"1","key":"436_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/QAI.0000000000001634","volume":"78","author":"SA Springer","year":"2018","unstructured":"\u2022 Springer SA, et al. Extended-release naltrexone improves viral suppression among incarcerated persons living with HIV with opioid use disorders transitioning to the community: results of a double-blind, placebo-controlled randomized trial. J Acquir Immune Defic Syndr. 2018;78(1):43\u201353. This study demonstrates improved viral suppression with extended-release naltrexone compared to placebo in persons living with HIV leaving incarceration.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"436_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e5945","volume":"345","author":"GJ MacArthur","year":"2012","unstructured":"MacArthur GJ, Minozzi S, Martin N, Vickerman P, Deren S, Bruneau J, et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ. 2012;345:e5945.","journal-title":"BMJ"},{"key":"436_CR14","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","volume":"357","author":"L Sordo","year":"2017","unstructured":"Sordo L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.","journal-title":"BMJ"},{"issue":"9","key":"436_CR15","first-page":"1049","volume":"6","author":"DS Metzger","year":"1993","unstructured":"Metzger DS, Woody GE, McLellan A, O'Brien CP, Druley P, Navaline H, et al. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr. 1993;6(9):1049\u201356.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"436_CR16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jsat.2007.08.004","volume":"35","author":"LE Sullivan","year":"2008","unstructured":"Sullivan LE, Moore BA, Chawarski MC, Pantalon MV, Barry D, O'Connor PG, et al. Buprenorphine\/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. J Subst Abus Treat. 2008;35(1):87\u201392.","journal-title":"J Subst Abus Treat"},{"key":"436_CR17","first-page":"CD002207","volume":"2","author":"RP Mattick","year":"2008","unstructured":"Mattick RP, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2008;2:CD002207.","journal-title":"Cochrane Database Syst Rev"},{"issue":"22","key":"436_CR18","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1001\/archinte.167.22.2469","volume":"167","author":"EF Wedam","year":"2007","unstructured":"Wedam EF, Bigelow GE, Johnson RE, Nuzzo PA, Haigney MC. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med. 2007;167(22):2469\u201375.","journal-title":"Arch Intern Med"},{"key":"436_CR19","doi-asserted-by":"crossref","unstructured":"Volpe DA, et al. Methadone metabolism and drug-drug interactions: in vitro and in vivo literature review. J Pharm Sci. 2018.","DOI":"10.1016\/j.xphs.2018.08.025"},{"issue":"Suppl 1","key":"436_CR20","doi-asserted-by":"publisher","first-page":"S89","DOI":"10.1086\/429503","volume":"41","author":"EF McCance-Katz","year":"2005","unstructured":"McCance-Katz EF. Treatment of opioid dependence and coinfection with HIV and hepatitis C virus in opioid-dependent patients: the importance of drug interactions between opioids and antiretroviral agents. Clin Infect Dis. 2005;41(Suppl 1):S89\u201395.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"436_CR21","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1521-0391.2009.00005.x","volume":"19","author":"EF McCance-Katz","year":"2010","unstructured":"McCance-Katz EF, Sullivan LE, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addict. 2010;19(1):4\u201316.","journal-title":"Am J Addict"},{"issue":"9651","key":"436_CR22","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/S0140-6736(08)61311-2","volume":"372","author":"BM Mathers","year":"2008","unstructured":"Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008;372(9651):1733\u201345.","journal-title":"Lancet"},{"issue":"2","key":"436_CR23","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1080\/10550881003684798","volume":"29","author":"MJ Kreek","year":"2010","unstructured":"Kreek MJ, Borg L, Ducat E, Ray B. Pharmacotherapy in the treatment of addiction: methadone. J Addict Dis. 2010;29(2):200\u201316.","journal-title":"J Addict Dis"},{"issue":"2","key":"436_CR24","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.drugalcdep.2006.02.003","volume":"84","author":"A Palepu","year":"2006","unstructured":"Palepu A, Tyndall MW, Joy R, Kerr T, Wood E, Press N, et al. Antiretroviral adherence and HIV treatment outcomes among HIV\/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend. 2006;84(2):188\u201394.","journal-title":"Drug Alcohol Depend"},{"key":"436_CR25","unstructured":"Once-monthly subcutaneous buprenorphine (Sublocade) for opioid use disorder. Med Lett Drugs Ther. 2018;60(1541):35\u201337."},{"issue":"3","key":"436_CR26","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1001\/jama.2016.9382","volume":"316","author":"RN Rosenthal","year":"2016","unstructured":"Rosenthal RN, Lofwall MR, Kim S, Chen M, Beebe KL, Vocci FJ, et al. Effect of buprenorphine implants on illicit opioid use among abstinent adults with opioid dependence treated with sublingual buprenorphine: a randomized clinical trial. JAMA. 2016;316(3):282\u201390.","journal-title":"JAMA"},{"issue":"6","key":"436_CR27","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1001\/jamainternmed.2018.1052","volume":"178","author":"MR Lofwall","year":"2018","unstructured":"Lofwall MR, Walsh SL, Nunes EV, Bailey GL, Sigmon SC, Kampman KM, et al. Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial. JAMA Intern Med. 2018;178(6):764\u201373.","journal-title":"JAMA Intern Med"},{"issue":"Suppl 1","key":"436_CR28","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1097\/QAI.0b013e318209751e","volume":"56","author":"FL Altice","year":"2011","unstructured":"Altice FL, Bruce RD, Lucas GM, Lum PJ, Korthuis PT, Flanigan TP, et al. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine\/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S22\u201332.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 1","key":"436_CR29","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1097\/QAI.0b013e3182097537","volume":"56","author":"DA Fiellin","year":"2011","unstructured":"Fiellin DA, Weiss L, Botsko M, Egan JE, Altice FL, Bazerman LB, et al. Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine\/naloxone. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S33\u20138.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 1","key":"436_CR30","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.1097\/QAI.0b013e31820bc9a5","volume":"56","author":"PT Korthuis","year":"2011","unstructured":"Korthuis PT, Fiellin DA, Fu R, Lum PJ, Altice FL, Sohler N, et al. Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S83\u201390.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"436_CR31","doi-asserted-by":"publisher","first-page":"605","DOI":"10.15288\/jsad.2013.74.605","volume":"74","author":"JS Potter","year":"2013","unstructured":"Potter JS, Marino EN, Hillhouse MP, Nielsen S, Wiest K, Canamar CP, et al. Buprenorphine\/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START). J Stud Alcohol Drugs. 2013;74(4):605\u201313.","journal-title":"J Stud Alcohol Drugs"},{"issue":"11","key":"436_CR32","doi-asserted-by":"publisher","first-page":"704","DOI":"10.7326\/0003-4819-152-11-201006010-00003","volume":"152","author":"GM Lucas","year":"2010","unstructured":"Lucas GM, et al. Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: a randomized trial. Ann Intern Med. 2010;152(11):704\u201311.","journal-title":"Ann Intern Med"},{"issue":"Suppl 1","key":"436_CR33","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1097\/QAI.0b013e318209754c","volume":"56","author":"PT Korthuis","year":"2011","unstructured":"Korthuis PT, Tozzi MJ, Nandi V, Fiellin DA, Weiss L, Egan JE, et al. Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S39\u201345.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"436_CR34","doi-asserted-by":"publisher","first-page":"e38335","DOI":"10.1371\/journal.pone.0038335","volume":"7","author":"SA Springer","year":"2012","unstructured":"Springer SA, Qiu J, Saber-Tehrani AS, Altice FL. Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners. PLoS One. 2012;7(5):e38335.","journal-title":"PLoS One"},{"issue":"9776","key":"436_CR35","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/S0140-6736(11)60358-9","volume":"377","author":"E Krupitsky","year":"2011","unstructured":"Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377(9776):1506\u201313.","journal-title":"Lancet"},{"issue":"2","key":"436_CR36","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/j.1369-1600.2007.00067.x","volume":"12","author":"BA Dijkstra","year":"2007","unstructured":"Dijkstra BA, et al. Does naltrexone affect craving in abstinent opioid-dependent patients? Addict Biol. 2007;12(2):176\u201382.","journal-title":"Addict Biol"},{"key":"436_CR37","first-page":"CD001333","volume":"4","author":"S Minozzi","year":"2011","unstructured":"Minozzi S, et al. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev. 2011;4:CD001333.","journal-title":"Cochrane Database Syst Rev"},{"key":"436_CR38","doi-asserted-by":"crossref","unstructured":"Lee JD, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2017.","DOI":"10.1016\/S0140-6736(17)32812-X"},{"issue":"12","key":"436_CR39","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1001\/jamapsychiatry.2017.3206","volume":"74","author":"L Tanum","year":"2017","unstructured":"Tanum L, Solli KK, Latif ZEH, Benth J\u0160, Opheim A, Sharma-Haase K, et al. Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial. JAMA Psychiatry. 2017;74(12):1197\u2013205.","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"436_CR40","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/j.1530-0277.2011.01601.x","volume":"36","author":"JM Tetrault","year":"2012","unstructured":"Tetrault JM, Tate JP, McGinnis KA, Goulet JL, Sullivan LE, Bryant K, et al. Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone. Alcohol Clin Exp Res. 2012;36(2):318\u201324.","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"436_CR41","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jsat.2014.02.008","volume":"47","author":"P Vagenas","year":"2014","unstructured":"Vagenas P, di Paola A, Herme M, Lincoln T, Skiest DJ, Altice FL, et al. An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone. J Subst Abus Treat. 2014;47(1):35\u201340.","journal-title":"J Subst Abus Treat"},{"issue":"1","key":"436_CR42","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/QAI.0000000000001759","volume":"79","author":"SA Springer","year":"2018","unstructured":"Springer SA, di Paola A, Barbour R, Azar MM, Altice FL. Extended-release naltrexone improves viral suppression among incarcerated persons living with HIV and alcohol use disorders transitioning to the community: results from a double-blind, placebo-controlled trial. J Acquir Immune Defic Syndr. 2018;79(1):92\u2013100.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"436_CR43","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.drugalcdep.2017.01.026","volume":"174","author":"SA Springer","year":"2017","unstructured":"Springer SA, di Paola A, Azar MM, Barbour R, Krishnan A, Altice FL. Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community. Drug Alcohol Depend. 2017;174:158\u201370.","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"436_CR44","doi-asserted-by":"publisher","first-page":"991","DOI":"10.15288\/jsad.2012.73.991","volume":"73","author":"MC Mitchell","year":"2012","unstructured":"Mitchell MC, Memisoglu A, Silverman BL. Hepatic safety of injectable extended-release naltrexone in patients with chronic hepatitis C and HIV infection. J Stud Alcohol Drugs. 2012;73(6):991\u20137.","journal-title":"J Stud Alcohol Drugs"},{"issue":"6","key":"436_CR45","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1111\/add.13753","volume":"112","author":"PT Korthuis","year":"2017","unstructured":"Korthuis PT, Lum PJ, Vergara-Rodriguez P, Ahamad K, Wood E, Kunkel LE, et al. Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot\/feasibility randomized trial. Addiction. 2017;112(6):1036\u201344.","journal-title":"Addiction"},{"key":"436_CR46","unstructured":"Clinical Trials Network-0067 Comparing Treatments for HIV-Infected Opioid Users in an Integrated Care Effectiveness Study (CHOICES) Scale-Up."},{"issue":"3","key":"436_CR47","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/j.1530-0277.2006.00052.x","volume":"30","author":"JL Dunbar","year":"2006","unstructured":"Dunbar JL, Turncliff RZ, Dong Q, Silverman BL, Ehrich EW, Lasseter KC. Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone. Alcohol Clin Exp Res. 2006;30(3):480\u201390.","journal-title":"Alcohol Clin Exp Res"},{"key":"436_CR48","unstructured":"Alkermes Inc., Vivitrol package insert. 2010."},{"issue":"1","key":"436_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/00952990.2010.540279","volume":"37","author":"AS Saber-Tehrani","year":"2011","unstructured":"Saber-Tehrani AS, Bruce RD, Altice FL. Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence. Am J Drug Alcohol Abuse. 2011;37(1):1\u201311.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"4","key":"436_CR50","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/j.1521-0391.2001.tb00519.x","volume":"10","author":"EF McCance-Katz","year":"2001","unstructured":"McCance-Katz EF, Rainey PM, Friedland G, Kosten TR, Jatlow P. Effect of opioid dependence pharmacotherapies on zidovudine disposition. Am J Addict. 2001;10(4):296\u2013307.","journal-title":"Am J Addict"},{"key":"436_CR51","unstructured":"International Advisory Panel on HIV Care Continuum Optimization. IAPAC Guidelines for Optimizing the HIV Care Continuum for Adults and Adolescents. J Int Assoc Provid AIDS Care. 2015:1\u201332."},{"issue":"6","key":"436_CR52","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1093\/cid\/ciq243","volume":"52","author":"EM Gardner","year":"2011","unstructured":"Gardner EM, McLees MP, Steiner JF, del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52(6):793\u2013800.","journal-title":"Clin Infect Dis"},{"key":"436_CR53","doi-asserted-by":"publisher","unstructured":"Williams AR, Nunes E, Olfson M. To battle the opioid overdose epidemic, deploy the \u2018Cascade of Care\u2019 model. Health Affairs Blog. 2017. https:\/\/doi.org\/10.1377\/hblog20170313.059163 .","DOI":"10.1377\/hblog20170313.059163"},{"issue":"12","key":"436_CR54","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1111\/add.13479","volume":"111","author":"ME Socias","year":"2016","unstructured":"Socias ME, Volkow N, Wood E. Adopting the \u2018cascade of care\u2019 framework: an opportunity to close the implementation gap in addiction care? Addiction. 2016;111(12):2079\u201381.","journal-title":"Addiction"},{"key":"436_CR55","unstructured":"National Institute on Drug Abuse. Chart of Evidence-Based Screening Tools and Assessments for Adults and Adolescents. Revised June 2018. https:\/\/www.drugabuse.gov\/nidamed-medical-health-professionals\/tool-resources-your-practice\/screening-assessment-drug-testing-resources\/chart-evidence-based-screening-tools . Accessed 3 January 2019."},{"issue":"4","key":"436_CR56","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2149","volume":"166","author":"PT Korthuis","year":"2017","unstructured":"Korthuis PT, McCarty D, Weimer M, Bougatsos C, Blazina I, Zakher B, et al. Primary care-based models for the treatment of opioid use disorder: a scoping review. Ann Intern Med. 2017;166(4):268\u201378.","journal-title":"Ann Intern Med"}],"container-title":["Current HIV\/AIDS Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11904-019-00436-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-019-00436-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-019-00436-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,10]],"date-time":"2022-09-10T23:28:15Z","timestamp":1662852495000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11904-019-00436-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,25]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["436"],"URL":"https:\/\/doi.org\/10.1007\/s11904-019-00436-7","relation":{},"ISSN":["1548-3568","1548-3576"],"issn-type":[{"value":"1548-3568","type":"print"},{"value":"1548-3576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,25]]},"assertion":[{"value":"25 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Korthuis serves as principal investigator for NIH-funded clinical trials that receive donated study medication from Alkermes (extended-release naltrexone) and Inidivior (buprenorphine\/naloxone). Dr. Fanucchi has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}